Akero Therapeutics to Present at H.C. Wainwright's 4th Annual NASH Virtual Investor Conference

Rhea-AI Summary

Akero Therapeutics (Nasdaq: AKRO) announced that CEO Andrew Cheng will present virtually at the H.C. Wainwright 4th Annual NASH Conference on October 5, 2020, at 12:00 p.m. E.T. The presentation will be accessible via a live webcast on the company's website, www.akerotx.com. Akero focuses on developing treatments for non-alcoholic steatohepatitis (NASH) with its lead product candidate, AKR-001, currently in a Phase 2a clinical trial. For more information, visit Akero's website.

SOUTH SAN FRANCISCO, Calif., Sept. 28, 2020 /PRNewswire/ -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage biotechnology company developing transformational treatments for patients with non-alcoholic steatohepatitis (NASH) and other serious metabolic disorders, today announced that Andrew Cheng, chief executive officer of Akero, will present virtually at the H.C. Wainwright 4^th Annual NASH Conference on Monday, October 5, 2020 at 12:00 p.m. E.T.

A live webcast of the presentation and Q&A will be available through the investor relations section of the Company's website at www.akerotx.com. Following the live webcast, an archived replay will be available on the Company's website.

About Akero Therapeutics
Akero is a cardio-metabolic NASH company dedicated to reversing the escalating NASH epidemic by developing pioneering medicines designed to restore metabolic balance and improve overall health of NASH patients. The Company's lead product candidate, AKR-001, is currently being evaluated in an ongoing Phase 2a clinical trial. Akero Therapeutics is headquartered in South San Francisco, CA.  For more information, please visit www.akerotx.com.

 

View original content to download multimedia:http://www.prnewswire.com/news-releases/akero-therapeutics-to-present-at-hc-wainwrights-4th-annual-nash-virtual-investor-conference-301139211.html

SOURCE Akero Therapeutics, Inc.

FAQ

When is Akero Therapeutics presenting at the H.C. Wainwright NASH Conference?

Akero Therapeutics will present on October 5, 2020, at 12:00 p.m. E.T.

Who will represent Akero Therapeutics at the NASH Conference?

CEO Andrew Cheng will represent Akero Therapeutics at the conference.

How can I watch Akero's presentation at the NASH Conference?

The presentation will be available via a live webcast on Akero's website at www.akerotx.com.

What is Akero Therapeutics' lead product candidate?

Akero's lead product candidate is AKR-001, currently in a Phase 2a clinical trial.

What is the focus of Akero Therapeutics?

Akero Therapeutics is focused on developing treatments for non-alcoholic steatohepatitis (NASH) and other metabolic disorders.